Launching an Immunotherapeutic Antibody Company

In 2012 and 2013 we worked with a local venture capital firm to evaluate all of the newly emerging immunotherapy checkpoint pathways. We selected the best possible pathways for prosecution in a carefully defined subset of cancers. Drug therapeutic profiles and pathway-specific preclinical development plans were then developed. This effort led to the establishment of the new company’s portfolio and evaluation of the clinical landscape into which their drugs would ultimately emerge – critical information that drove the  preclinical development strategy, specifically, to identify novel combination therapies that would be attractive in treating specific cancers. The firm then successfully used this innovative strategic positioning in its pitch for syndication. The firm was able to attract not only additional venture capital investment also investment from a top-10 pharmaceutical company.